Objective Type 2 diabetes (T2D) is associated with increased mortality in ethnically diverse populations, although the extent to which this association is genetically determined is unknown.

Semaglutide received its first FDA approval back in 2017; at the time, it was only indicated for T2D to improve patients’ glucose and was recommended alongside exercise and dietary modifications.

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

Approximately 422 million adults worldwide develop T2D. However, this condition can be reversed through weight management and dietary intervention. The DiRECT trial findings indicated that ...